Investors of ADMA Biologics, Inc. Notified About Class Action Lawsuit Deadline

Important Notice for ADMA Biologics Shareholders

In a recent announcement, Kahn Swick & Foti, LLC (KSF) has reached out to investors of ADMA Biologics, Inc. regarding a class action securities lawsuit that is currently ongoing. The firm, led by former Louisiana Attorney General Charles C. Foti, Jr., has identified a significant deadline that all affected investors need to be aware of. The application deadline is set for August 10, 2026.

Who is Affected?

This lawsuit is aimed at assisting investors who purchased ADMA Biologics, Inc. securities between August 9, 2024, and March 25, 2026. During this period, certain actions by the company and its executives allegedly misled investors, leading to substantial financial losses. The legal proceedings are currently taking place in the United States District Court for the District of New Jersey, under the case name Mazzarino v. ADMA Biologics, Inc., et al, No. 26-cv-04793.

Allegations Against ADMA Biologics

The crux of the lawsuit revolves around claims that ADMA Biologics and specific executives failed to disclose critical information that affected the financial outlook of the company. The allegations include:
1. Undisclosed Related Party Transactions: Claims state that the company engaged in transactions that were not disclosed to investors, raising questions about transparency.
2. Channel Stuffing Practices: The lawsuit alleges that the company inflated revenue figures through questionable practices, creating a false impression of its financial health.
3. Insufficient Internal Controls: The company is accused of lacking adequate internal controls, putting investor capital at further risk.

Investors' Rights and What to Do

For investors who suffered losses during the stated class period, it is crucial to take immediate action. Potential lead plaintiffs can request to be recognized by the court until the August 10 deadline. However, it's important to note that not all affected investors need to serve as lead plaintiffs to qualify for potential recovery.

For further information about the lawsuit or to assess eligibility, investors can reach out to KSF Managing Partner, Lewis Kahn, at 1-833-538-3666, or via email at [email protected]. Detailed information is also available on their website, Kahn Swick & Foti, where investors can learn more about their rights and possible next steps.

About Kahn Swick & Foti, LLC

KSF is recognized as one of the nation’s leading boutique law firms specializing in securities litigation. With a strong track record, including a ranking among the top firms nationally relative to settlement values, KSF provides representation for both institutional and retail investors. Their offices are strategically located throughout major cities across the United States, marking them as a significant player in the realm of investment recovery.

For those potentially affected by the actions of ADMA Biologics, this notice serves as both a reminder and a crucial call to action to investigate their rights as investors and participate in the ongoing legal battle.